SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 278.98 |
| Enterprise Value ($M) | 271.46 |
| Book Value ($M) | 9.56 |
| Book Value / Share | 0.18 |
| Price / Book | 29.19 |
| NCAV ($M) | 7.73 |
| NCAV / Share | 0.15 |
| Price / NCAV | 36.08 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.80 |
| Return on Assets (ROA) | -1.94 |
| Return on Equity (ROE) | -2.76 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.92 |
| Current Ratio | 13.92 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8.79 |
| Assets | 10.62 |
| Liabilities | 1.06 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.03 |
| Operating Income | -8.37 |
| Net Income | -8.38 |
| Earnings Per Shares Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -4.99 |
| Cash from Investing | -0.40 |
| Cash from Financing | 11.94 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 4.90 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 36,282 | 107,574 | 33.73 | |
| 1,605,217 | 3,964,949 | 40.49 | |
| 635,512 | 2,157,361 | 29.46 | |
| 2,438,322 | 6,873,286 | 35.48 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CALC – CalciMedica, Inc. | CAPR – Capricor Therapeutics, Inc. |
| CASI – CASI Pharmaceuticals, Inc. | CDTX – Cidara Therapeutics, Inc. |
| CELU – Celularity Inc. |
Financial data and stock pages provided by
Fintel.io